2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Taipei Medical University, SPARK Taiwan

An automatic plasma testing for breast cancer detection.

Future Company Type

Biotechnology

Prestartup

Expecting startup year /2021

No. of team members /5

Stage

Development

Presenter

Name /Sheng-Chao Wang

Title /Ph.D. Student

Email /wsc0327@gmail.com

Telephone /(Work) (886)-2-27361661#6183

Fax /(886)-2-27361661#6162

Mobile /(886)-978-315-760

About the Team

EPICAnTM is a medical research team focused on commercializing early cancer detection with liquid biopsies. We promise “easy to Predict, We can”. We use the real-time methylation-specific PCR by checking three hypermethylated gene biomarkers of plasma’s cell-free DNA to be a high accurate detection of breast cancer. We have established an automatic process. The result could provide clinicians an early intervention suggestion to improve early diagnosis confidence. We can and we will detect cancer easily and quickly.

Brief Description of main products or services

An automatic blood test for the early detection of breast cancer. Our aim is to supply a new non-invasive, rapid, accurate, and precise screening test for breast cancer.

  • Low-invasive: Blood-based test.
  • Accuracy: The technique reveals a high-accuracy early detection model for breast cancer with a sensitivity of 93.0%, a specificity of 93.0%, AUC of 0.930.
  • Rapid: The ccfDNA extraction and chemically modification in one machine shortening the process to complete within 5 hours.
  • Precision: Automatic process to reduce artificial errors.
  • Global markers: We identified biomarkers in Taiwanese and TCGA breast cancer patients using genome-wide methylation array and next evaluated in paired 109 tumors and normal tissues of breast cancer patients and 342 plasma specimens.
  • Other clinical applications:
    1. Combined analysis with mammography and ultrasonography can lower the false-positive rate of breast cancer screening.
    2. Treatment response monitoring: The aberrant methylated ccfDNA biomarkers are disappeared when followed by surgery and adjuvant treatment.
  • Patents: Done filed PCT and Taiwan patent application
  • Company objectives: Raise capital for
    1. A prototype for the testing kit enable to reach to 1000 clinical sample size;
    2. GMP manufacturer OEM production;
    3. Apply for TFDA and FDA approval.

Contact Person

Name /Sheng-Chao Wang (Ace)

Phone /(886)-978-315-760

Email /wsc0327@gmail.com